Related Experiment Video
Updated: Oct 11, 2025
12:36
A Human Corneal Organ Culture Model of Descemet's Stripping Only with Accelerated Healing Stimulated by Engineered Fibroblast Growth Factor 1
Published on: July 22, 2022
4.7K
Descemet Stripping Only for Fuchs Endothelial Corneal Dystrophy: Will It Become the Gold Standard?
1Department of Ophthalmology, NYU Grossman School of Medicine, New York, NY.
Cornea
|December 5, 2021
Abstract:
Descemet stripping only (DSO) has become a viable treatment option for certain cases of Fuchs Endothelial Corneal Dystrophy (FECD). This article describes the history of the development of DSO, its current status, and what successful DSO tells us about the pathophysiology of FECD. Remaining questions and future directions are also highlighted.
